---
document_datetime: 2024-05-16 14:37:52
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/temozolomide-teva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: temozolomide-teva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 13.8495875
conversion_datetime: 2025-12-25 08:36:19.18132
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Temozolomide Teva

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope   | Opinion/ 1 issued on   | Commissio n Decision Issued 2 /   | Product affected 3   | Summary   | Summary   |
|----------------------|---------|------------------------|-----------------------------------|----------------------|-----------|-----------|
|                      |         | Notification           | amended                           | Information          |           |           |
|                      |         |                        | on                                |                      |           |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000170853   | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted   | 07/03/2024   | Annex II and PL   |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------------------|